Skip to main content
. 2023 Mar 13;11:e15025. doi: 10.7717/peerj.15025

Table 2. Clinicopathologic characteristics according to resected lymph nodes group and metastasized lymph nodes group.

Variables Resected lymph nodes Metastasized lymph nodes
≤10 >10 P value ≤10 >10 P value
Age (years) 0.118 0.636
≤50 30 (40.0) 44 (52.4) 63 (47.4) 11 (42.3)
>50 45 (60.0) 40 (47.6) 70 (52.6) 15 (57.7)
Gender 0.036 0.013
Male 26 (34.7) 43 (51.2) 52 (39.1) 17 (65.4)
Female 49 (65.3) 41 (48.8) 81 (60.9) 9 (34.6)
Tumor size (cm) 0.004 0.027
≤2 cm 62 (82.7) 52 (61.9) 100 (75.2) 14 (53.8)
>2 cm 13 (17.3) 32 (38.1) 33 (24.8) 12 (46.2)
Multifocality 0.016 0.021
Yes 14 (18.7) 30 (35.7) 32 (24.1) 12 (46.2)
No 61 (81.3) 54 (64.3) 101 (75.9) 14 (53.8)
Extrathyroidal extension 0.059 0.076
Yes 23 (30.7) 38 (45.2) 47 (35.3) 14 (53.8)
No 52 (69.3) 46 (54.8) 86 (64.7) 12 (46.2)
Bilateral 0.512 0.063
Yes 5 (6.7) 8 (9.5) 8 (6.0) 5 (19.2)
No 70 (93.3) 76 (90.5) 125 (94.0) 21 (80.8)
Preoperative calcitonin <0.001 <0.001
≤300 ng/L 46 (63.0) 13 (16.2) 59 (46.1) 0 (0.0)
>300 ng/L 27 (37.0) 67 (83.8) 69 (53.9) 25 (100.0)
Pathologic T classification 0.031 0.057
T1/T2 51 (68.0) 43 (51.2) 83 (62.4) 11 (42.3)
T3/T4 24 (32.0) 41 (48.8) 50 (37.6) 15 (57.7)
Pathologic N classification <0.001 <0.001
pN0 58 (77.3) 12 (14.3) 70 (52.6) 0 (0.0)
pN1a 15(20.0) 7 (8.3) 21 (15.8) 1 (3.8)
pN1b 2 (2.7) 65 (77.4) 42 (31.6) 25 (96.2)
AJCC clinical stage <0.001 <0.001
I/II 52 (69.3) 12 (14.3) 64 (48.1) 0 (0.0)
III/IV 23 (30.7) 72 (85.7) 69 (51.9) 26 (100.0)
Recurrence <0.001 0.025
Yes 3 (4.0) 21 (25.3) 16 (12.0) 8 (32.0)
No 72 (96.0) 62 (74.7) 117 (88.0) 17 (68.0)
Death 0.001 0.217
Yes 0 (0.0) 12 (14.5) 8 (6.1) 4 (15.4)
No 75 (100.0) 71 (85.5) 124 (93.9) 22 (84.6)

Note:

The bold part of the P value represents P < 0.05.